Amredobresib

For research use only. Not for therapeutic Use.

  • CAT Number: I045122
  • CAS Number: 1610044-98-8
  • Molecular Formula: C26H29N9
  • Molecular Weight: 467.57
  • Purity: ≥95%
Inquiry Now

Amredobresib is a potent inhibitor of BET. Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription. Amredobresib is useful for the research of acute myeloid leukemia (AML) and cancer (extracted from patent WO2019145410A1 and WO2021175824A1)[1].


Catalog Number I045122
CAS Number 1610044-98-8
Synonyms

6-[1-benzyl-6-(4-methylpiperazin-1-yl)benzimidazol-2-yl]-N,3-dimethyl-[1,2,4]triazolo[4,3-a]pyrazin-8-amine

Molecular Formula C26H29N9
Purity ≥95%
InChI InChI=1S/C26H29N9/c1-18-30-31-26-24(27-2)28-22(17-34(18)26)25-29-21-10-9-20(33-13-11-32(3)12-14-33)15-23(21)35(25)16-19-7-5-4-6-8-19/h4-10,15,17H,11-14,16H2,1-3H3,(H,27,28)
InChIKey JLUUVUUYIXBDCG-UHFFFAOYSA-N
SMILES CC1=NN=C2N1C=C(N=C2NC)C3=NC4=C(N3CC5=CC=CC=C5)C=C(C=C4)N6CCN(CC6)C
Reference

[1]. Ulrike Tontsch-Grunt, et al. Combination treatment of acute myeloid leukemia. Patent WO2019145410A1.

[2]. Shaonan Wang, et al. Method for administration of an anti cancer agent. Patent WO2021175824A1.

Request a Quote